Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab as First-line Treatment in Cisplatin-ineligible Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma

NCT03473756 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03473756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03473756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab as First-line Treatment in Cisplatin-ineligible Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
May 15, 2018
Completion date
July 10, 2024
Enrollment
37 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma